---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010821"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2022-07-19T23:59:59+00:00"
generated_at: "2026-06-24T12:02:41.823756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Capricor dosed first patient in Phase 3 HOPE-3 trial of CAP-1002 for Duchenne MD

## Summary
- First patient dosed in randomized, double-blind, placebo-controlled HOPE-3 trial enrolling ~70 patients in U.S.
- CAP-1002 is a cell therapy for late-stage Duchenne muscular dystrophy; Phase 2 data showed up to 70% slowing of upper limb function loss.
- Primary endpoint is Performance of the Upper Limb 2.0; RMAT and Orphan Drug designations support regulatory pathway.
- Nippon Shinyaku partnership provides funding and commercialization rights in U.S.; Capricor holds rest-of-world rights.

## SEC filing metadata
- accession: 0001558370-22-010821
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2022-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837022010821/0001558370-22-010821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837022010821/capr-20220719x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010821
- JSON: https://secwatch.observer/filing/0001558370-22-010821.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.